» Articles » PMID: 24091600

Mechanisms of STAT3 Activation in the Liver of FXR Knockout Mice

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Farnesoid X receptor (FXR, Nr1h4) is a ligand-activated transcription factor belonging to the nuclear receptor superfamily. FXR is essential in maintaining bile acid (BA) homeostasis, and FXR(-/-) mice develop cholestasis, inflammation, and spontaneous liver tumors. The signal transducer and activator of transcription 3 (STAT3) is well known to regulate liver growth, and STAT3 is feedback inhibited by its target gene, the suppressor of cytokine signaling 3 (SOCS3). Strong activation of STAT3 was detected in FXR(-/-) mouse livers. However, the mechanism of STAT3 activation with FXR deficiency remains elusive. Wild-type (WT) and FXR(-/-) mice were used to detect STAT3 pathway activation in the liver. In vivo BA feeding or deprivation was used to determine the role of BAs in STAT3 activation, and in vitro molecular approaches were used to determine the direct transcriptional regulation of SOCS3 by FXR. STAT3 was activated in FXR(-/-) but not WT mice. BA feeding increased, but deprivation by cholestyramine reduced, serum inflammatory markers and STAT3 activation. Furthermore, the Socs3 gene was determined as a direct FXR target gene. The elevated BAs and inflammation, along with reduced SOCS3, collectively contribute to the activation of the STAT3 signaling pathway in the liver of FXR(-/-) mice. This study suggests that the constitutive activation of STAT3 may be a mechanism of liver carcinogenesis in FXR(-/-) mice.

Citing Articles

Gut Microbiota, Deranged Immunity, and Hepatocellular Carcinoma.

Scarpellini E, Scarlata G, Santori V, Scarcella M, Kobyliak N, Abenavoli L Biomedicines. 2024; 12(8).

PMID: 39200261 PMC: 11351762. DOI: 10.3390/biomedicines12081797.


Current Perspectives on the Molecular and Clinical Relationships between Primary Biliary Cholangitis and Hepatocellular Carcinoma.

Floreani A, Gabbia D, De Martin S Int J Mol Sci. 2024; 25(4).

PMID: 38396870 PMC: 10888596. DOI: 10.3390/ijms25042194.


Unveiling the complex relationship between gut microbiota and liver cancer: opportunities for novel therapeutic interventions.

Rajapakse J, Khatiwada S, Akon A, Yu K, Shen S, Zekry A Gut Microbes. 2023; 15(2):2240031.

PMID: 37615334 PMC: 10454000. DOI: 10.1080/19490976.2023.2240031.


Pleiotropic roles of FXR in liver and colorectal cancers.

Huang X, Fan M, Huang W Mol Cell Endocrinol. 2022; 543:111543.

PMID: 34995680 PMC: 8818033. DOI: 10.1016/j.mce.2021.111543.


Farnesoid X receptor activation induces antitumour activity in colorectal cancer by suppressing JAK2/STAT3 signalling via transactivation of SOCS3 gene.

Li S, Xu Z, Guo J, Zheng J, Sun X, Yu J J Cell Mol Med. 2020; 24(24):14549-14560.

PMID: 33164339 PMC: 7754034. DOI: 10.1111/jcmm.16083.


References
1.
Zhang S, Liu Q, Wang J, Harnish D . Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists. Biochem Biophys Res Commun. 2009; 379(2):476-9. DOI: 10.1016/j.bbrc.2008.12.117. View

2.
Lee C, Kim Y, Kim E, Meng Z, Huang W, Hwang S . Farnesoid X receptor protects hepatocytes from injury by repressing miR-199a-3p, which increases levels of LKB1. Gastroenterology. 2012; 142(5):1206-1217.e7. PMC: 3578415. DOI: 10.1053/j.gastro.2012.01.007. View

3.
Ogata H, Kobayashi T, Chinen T, Takaki H, Sanada T, Minoda Y . Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology. 2006; 131(1):179-93. DOI: 10.1053/j.gastro.2006.04.025. View

4.
Croker B, Krebs D, Zhang J, Wormald S, Willson T, Stanley E . SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol. 2003; 4(6):540-5. DOI: 10.1038/ni931. View

5.
Hwang S, Urizar N, Moore D, Henning S . Bile acids regulate the ontogenic expression of ileal bile acid binding protein in the rat via the farnesoid X receptor. Gastroenterology. 2002; 122(5):1483-92. DOI: 10.1053/gast.2002.32982. View